Compare Johnson Controls International PLC (JCI) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Johnson Controls International PLC trades at $151.1 (market cap $92.34B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Johnson Controls International PLC is far larger — about 94.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Johnson Controls International PLC pays a 1.05% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 66 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| JCI | MRVI | |
|---|---|---|
Market Cap | $92.34B | $977.37M |
Volume | 5,497,477 | 2,742,564 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $9.00 |
52-Week Low | $108.54 | $2.83 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $101.17B | $1.08B |
Dividend Yield | 1.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $156.47, up 0.68% today, with a bullish technical outlook and strong institutional support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.58. Revenue for 2025 was $23.60B, with net income surging to $3.29B, reflecting a robust profit margin of 13.94%. Recent news highlights strong Q3 2026 results and raised full-year guidance, driven by demand in data-center thermal management systems.
JCI presents a favorable investment case with solid fundamentals, analyst consensus pointing to a $172.50 price target, and no sell ratings among 45 analysts. Key risks include rising debt-to-asset ratios and macroeconomic sensitivity. The stock's valuation multiples are elevated, but growth in high-margin segments supports upside potential. Institutional ownership trends show increased positions, reinforcing confidence in the company's strategic direction.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
